NCT05039086View on ClinicalTrials.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

CompletedOBSERVATIONAL
Enrollment

13,021

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

October 4, 2022

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

PDE5 inhibitor

PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.

DRUG

Endothelin Receptor Antagonists

Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Rutgers University

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Brigham and Women's Hospital

OTHER